Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 8,281–8,340 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

University of Milano-Bicocca1 University of Minnesota Advanced Research Diagnostic Laboratory1 University of Montreal1 University of Muenster1 University of Nebraska Medical Centre1 University of New Brunswick1 University of Newcastle HREC1 University of Newcastle upon Tyne1 University of Nigeria Teaching Hospital1 University of North Carolina IUCAC1 University of North Carolina Thurston Arthritis Research Center1 University of North Carolina at Chapel Hill Institutional Review Board1 University of Notre Dame Australia1 University of Oklahoma1 University of Oklahoma Health Sciences Center1 University of Oldenburg1 University of Osaka Hospital1 University of Oslo1 University of Ottawa Heart Institute1 University of Ottawa Research Ethics Board1 University of Padua1 University of Perugia1 University of Pittsburgh Medical Center1 University of Pittsburgh School of Medicine1 University of Pécs1 University of Rwanda1 University of San Carlos–Extension1 University of Santo Amaro1 University of Saskatchewan1 University of Social Welfare and Rehabilitation Sciences1 University of Sorocaba1 University of South Australia1 University of South Australia HREC1 University of South China1 University of Southern California Keck School of Medicine1 University of Stirling1 University of São Paulo1 University of Texas MD Anderson Cancer Center1 University of Texas Physicians1 University of Texas at Austin1 University of Texas – Houston1 University of Tokyo1 University of Toronto Lupus Clinic1 University of Tsukuba Hospital1 University of Turin1 University of Ulm1 University of Utah Heritage 1000 Projects1 University of Vermont1 University of Vermont Institutional Review Board1 University of Verona1 University of Victoria1 University of Virginia Flow Cytometry Core1 University of Warwick1 University of Winchester1 University of Wisconsin Carbone Cancer Center1 University of Wisconsin Carbone Cancer Centre1 University of Wisconsin Institutional Animal Care and Use Committee1 University of Wisconsin Institutional Review Board1 University of Wolverhampton1 University of Würzburg1

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 311 of 946

463 Dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastases

jitc · abstract · 2025-11-04 · 2 matching annotations

80.3%

J Clin Oncol ipilimumab enzalutamide metastatic castration-resistant prostate cancer mCRPC pancreatic ductal carcinoma prostate cancer Atezolizumab

…static chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–7.Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkop…

470 Multimodal profiling reveals unique and overlapping features of rilvegostomig and PD(x) activity in NSCLC tumor explants

jitc · abstract · 2025-11-04 · 2 matching annotations

80.7%

HBS regulatory board NCT04995523 Rilvegostomig non-small cell lung cancer NSCLC

…eca Human Biological Sample global standard and approved by the HBS regulatory board. All samples used for these work were collected from patients t…

480 Targeting CHCHD3 – cGAS axis: a strategy to remodel the immunosuppressive microenvironment in lung adenocarcinoma with translational implications

jitc · abstract · 2025-11-04 · 2 matching annotations

89.8%

Tianjin Medical University Cancer Institute and Hospital Tianjin Cancer Institute and Hospital TN4510 lung adenocarcinoma CHCHD3 LUAD neoadjuvant chemoimmunotherapy

…ens and information was approved by the Ethics Committee of the Tianjin Medical University Cancer Institute and Hospital (Approve number: bc2022323). All animal experiments were perfor…

481 UCHL1 hijacks tolerogenic dendritic cell maturation and promotes mregDC-Treg crosstalk to nullify checkpoint blockade

jitc · abstract · 2025-11-04 · 2 matching annotations

89.2%

Fudan University Zhongshan Hospital Atezolizumab Bevacizumab Atezo/Bev HCC hepatocellular carcinoma Immune-checkpoint blockade therapies

…udy was approved by the Ethics Committee of Zhongshan Hospital, Fudan University (IRB number: B2021-464).Consent Written informed consent was ob…

491 A single-arm clinical trial of iNeo-Vac-R01 for advanced digestive system tumors refractory to standard therapy

jitc · abstract · 2025-11-04 · 2 matching annotations

97.0%

Zhejiang University School of Medicine Sir Run Run Shaw Hospital iNeo-Vac-R01 pancreatic cancer gastric cancer cholangiocarcinoma esophageal cancer advanced digestive system malignancies

…ethics committees of Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine. The ID of the approval is 2023-0465. Written informed consent …

493 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.1%

West China Hospital of Sichuan University Institutional Review Board CRC Akk immunotherapy ClinicalTrials.gov MSS CRC PD-1 inhibitors

…number: NCT06865521).All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…

494 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.3%

West China Hospital of Sichuan University Akk Institutional Review Board CRC immunotherapy ClinicalTrials.gov MSS CRC

…umber: NCT06865521). All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…

498 Integrated scRNAseq, TCR repertoire and spatial transcriptomic analysis reveals immune remodeling induced by combined BRAF/MEK/PD-1 inhibition in metastatic BRAFV600E colorectal cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

80.7%

…23;29(2):458–466.Ethics Approval This study was approved by the DF/HCC IRB as protocol 18-144 (see also ClinicalTrials.gov NCT03668431).…

500 Biomarker identification of early response and resistance to combinatorial anti-angiogenic and immune-checkpoint blockade therapy in the recurrent ovarian cancer setting

jitc · abstract · 2025-11-04 · 2 matching annotations

90.7%

EORTC-1508GCG atezolizumab bevacizumab atezolizumab-containing High-grade serous ovarian cancer aspirin PROC low-dose aspirin PD-L1 blockade platinum-resistant ovarian cancer+1 more

…elial barrier, potentially synergizing with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab…

502 Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC

jitc · abstract · 2025-11-04 · 2 matching annotations

89.1%

Mayo Clinic South Central - Oxford TG4050 HNSCC NCT04183166

…00 (EudraCT 2018-003267-58) Initial approval on 26 Mar 2020 US: Mayo Clinic Institutional Review Boards ID: 20-007421 Initial approval on 1…

504 Biological mechanisms of resistance to macrophage checkpoint inhibitors in relapsed B-cell non-Hodgkin lymphoma

jitc · abstract · 2025-11-04 · 2 matching annotations

87.8%

NCT05025800 Clin Cancer Res evorpacept lenalidomide rituximab B-cell non-hodgkin lymphoma B-NHL ALX148

…checkpoint inhibitor.Methods In this single-arm phase 1 trial ( NCT05025800), adult patients with relapsed indolent B-NHL received evorpace…

516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors

jitc · abstract · 2025-11-04 · 2 matching annotations

92.7%

Memorial Sloan Kettering Cancer Center Institutional Review Board Columbia University Institutional Review Board rituximab tocilizumab bullous pemphigoid prednisone arthritis osteoporosis

…view Board (IRB # AAAS9173). The study was also approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB protocol number: 21-519).Abstract 516 Figure 1Tocilizumab …